ES2549192T3 - Construcción de expresión de ADN - Google Patents

Construcción de expresión de ADN Download PDF

Info

Publication number
ES2549192T3
ES2549192T3 ES11801756.5T ES11801756T ES2549192T3 ES 2549192 T3 ES2549192 T3 ES 2549192T3 ES 11801756 T ES11801756 T ES 11801756T ES 2549192 T3 ES2549192 T3 ES 2549192T3
Authority
ES
Spain
Prior art keywords
dna
dna expression
construct
expression construction
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11801756.5T
Other languages
English (en)
Inventor
Matthias Schroff
Christiane Kleuss
Kerstin KAPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mologen AG
Original Assignee
Mologen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2549192(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mologen AG filed Critical Mologen AG
Application granted granted Critical
Publication of ES2549192T3 publication Critical patent/ES2549192T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Una construcción de ADN para expresión génica, en la que la construcción es una doble cadena de ADN lineal y de cadena abierta que comprende una secuencia promotora, una secuencia de codificación y una señal de terminación, en donde la construcción comprende al menos un nucleótido L-ADN y en la que al menos un nucleótido L-ADN está comprendido en el interior de los cinco últimos nucleótidos de un extremo 5' y/o 3'.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES11801756.5T 2010-12-23 2011-12-23 Construcción de expresión de ADN Active ES2549192T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1021873.3A GB201021873D0 (en) 2010-12-23 2010-12-23 DNA expression construct
GB201021873 2010-12-23
PCT/EP2011/073984 WO2012085282A1 (en) 2010-12-23 2011-12-23 Dna expression construct

Publications (1)

Publication Number Publication Date
ES2549192T3 true ES2549192T3 (es) 2015-10-23

Family

ID=43598917

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11801756.5T Active ES2549192T3 (es) 2010-12-23 2011-12-23 Construcción de expresión de ADN

Country Status (20)

Country Link
US (1) US20130287814A1 (es)
EP (1) EP2655620B1 (es)
JP (2) JP6377349B2 (es)
KR (1) KR101517365B1 (es)
CN (1) CN103370413B (es)
AU (1) AU2011347086B2 (es)
BR (1) BR112013015819A2 (es)
CA (1) CA2822367A1 (es)
DK (1) DK2655620T3 (es)
ES (1) ES2549192T3 (es)
GB (1) GB201021873D0 (es)
HK (1) HK1188608A1 (es)
IL (1) IL227104A (es)
MX (1) MX343699B (es)
PL (1) PL2655620T3 (es)
PT (1) PT2655620E (es)
RU (1) RU2604186C2 (es)
SG (1) SG191327A1 (es)
WO (1) WO2012085282A1 (es)
ZA (1) ZA201304998B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201021873D0 (en) * 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
EP3508198A1 (en) 2014-06-04 2019-07-10 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) * 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
EP3854419A1 (en) * 2020-01-24 2021-07-28 Univerzita Karlova, Lekarska fakulta v Plzni Dna conjugate and method of transformation of genes into cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2138553C1 (ru) * 1991-09-30 1999-09-27 Берингер Ингельгейм Интернациональ ГмбХ Трансфекционная композиция для высших эукариотных клеток, комплекс нуклеиновой кислоты, пригодный в качестве компонента трансфекционной композиции, конъюгат, пригодный в качестве компонента трансфекционной композиции, эндосомолитический пептид, пригодный в качестве компонента трансфекционной композиции
TW480282B (en) * 1996-04-24 2002-03-21 Ren Wen Corp Recombinant eucaryotic vector containing allergen gene and use of preventing and treating allergic disease thereof
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
WO2003023000A2 (en) * 2001-09-07 2003-03-20 Baylor College Of Medicine Linear dna fragments for gene expression
WO2004016786A2 (de) * 2002-07-19 2004-02-26 Mologen Ag Dna-expressionskonstrukt zur multiplen genexpression
ATE502957T1 (de) * 2004-06-23 2011-04-15 Usv Ltd Chimeres, von den placenta- und hypophysenisoformen abgeleitetes humanes wachstumshormon und verfahren zur gewinnung der chimere
WO2009035554A2 (en) * 2007-09-07 2009-03-19 University Of Florida Research Foundation, Inc. Superior structure stability and selectivity of hairpin nucleic acid probes with an l-dna stem
GB201021873D0 (en) * 2010-12-23 2011-02-02 Mologen Ag DNA expression construct

Also Published As

Publication number Publication date
IL227104A (en) 2017-02-28
JP2018007669A (ja) 2018-01-18
JP6377349B2 (ja) 2018-08-22
KR101517365B1 (ko) 2015-05-06
PT2655620E (pt) 2015-10-26
PL2655620T3 (pl) 2016-01-29
AU2011347086B2 (en) 2015-07-16
CN103370413A (zh) 2013-10-23
CN103370413B (zh) 2016-06-01
AU2011347086A1 (en) 2013-07-25
RU2604186C2 (ru) 2016-12-10
EP2655620A1 (en) 2013-10-30
MX343699B (es) 2016-11-16
WO2012085282A1 (en) 2012-06-28
SG191327A1 (en) 2013-07-31
GB201021873D0 (en) 2011-02-02
EP2655620B1 (en) 2015-08-12
KR20130107350A (ko) 2013-10-01
BR112013015819A2 (pt) 2018-05-29
ZA201304998B (en) 2014-03-26
CA2822367A1 (en) 2012-06-28
DK2655620T3 (en) 2015-11-09
MX2013007285A (es) 2013-09-26
JP2014508512A (ja) 2014-04-10
HK1188608A1 (en) 2014-05-09
RU2013132149A (ru) 2015-01-27
US20130287814A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
ES2549192T3 (es) Construcción de expresión de ADN
CL2012001068A1 (es) Polinucleotido que codifica oleosina modificada incluyendo al menos una cisteina introducida artificialmente, constructo genetico que comprende dicho polinucleotido; célula huesped; composicion que comprende un cuerpo oleoso; alimento animal que comprende el cuerpo oleoso.
BRPI0817811A2 (pt) Xilanases, ácidos nucleicos que codificam as mesmas e métodos para fabricação e uso das mesmas.
BRPI0822218A2 (pt) Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las.
AR079883A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
AR079881A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
AR079882A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
ES2566033T3 (es) Parvovirus recombinante atenuado
NI201001032A (es) Formas crsitalinas de dimetoxi docetaxel y metodo para preparar el mismo.
BRPI0811610A2 (pt) Aço com baixa densidade, apresentando uma boa aptidão ao encaixe
AU308859S (en) Racking beam of indefinite length and fixed cross-section
CL2008001389A1 (es) Panel para la construccion compuesto por un panel de material aislante que consta de medios que sobresalen prolongandose desde una cara del panel.
ES1067846Y (es) Cubo para friegasuelos con doble compartimentacion
BRPI0909051A2 (pt) Indicador do tempo de vida restante para bens de consumo perecíveis.
JP2013541099A5 (es)
CY1124624T1 (el) Μητρες οι οποιες περιεχουν εναν τροποποιημενο πολυσακχαριτη
IL287354A (en) Double-helical nucleic acid molecules with shortened sense bands
BRPI0911621A2 (pt) filamento de aço patenteado em bismuto.
ES2599153T3 (es) Molécula de ARNi para la timidilato sintasa y uso de la misma
IT1393191B1 (it) Struttura di raffreddamento per una trasmissione a variazione continua del tipo a cinghia.
DK2310499T3 (da) Mikroorganisme, der udtrykker aldose-1-epimerase
DOP2010000308A (es) Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica
JP2012513655A5 (es)
BRPI0913586A8 (pt) combinação, e, uso de uma combinação.
ES2647576T3 (es) Prueba genética para la predisposición genética a la hemofilia A en bichones habaneros